ARS Pharma Presents Real-World Efficacy of Neffy® at ACAAI Meeting
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) is set to unveil significant findings at the upcoming annual meeting of the American College of Allergy, Asthma & Immunology (ACAAI). With a strong commitment towards enhancing patient care in cases of anaphylaxis, ARS Pharma will present a late-breaking oral presentation alongside six poster presentations. These showcases emphasize the impactful real-world outcomes associated with neffy®, an innovative epinephrine nasal spray.
Key Findings from Presentations
One of the most noteworthy findings from the oral presentation reveals that approximately nine out of ten patients experiencing anaphylaxis responded effectively to a single dose of neffy®. This treatment marks a significant advancement in anaphylaxis management, particularly in situations involving oral food challenges or allergy immunotherapy.
Real-World Data Insights
Healthcare professionals presenting at the ACAAI meeting will detail case studies that reflect the successful application of neffy. The feedback from healthcare providers illustrates a growing confidence in this needle-free alternative, showcasing its ability to mirror the effectiveness traditionally associated with injectable epinephrine.
Expert Opinions Support Neffy's Efficacy
Dr. Jonathan Spergel, a leading expert in allergies, emphasized the significance of these results stating, “The consistent outcomes across various patient demographics affirm that intranasal epinephrine not only offers convenience but is equally effective in treating anaphylaxis.” This statement underlines the potential for improved patient experiences, especially in emergency scenarios.
Expanding Research on Neffy
According to Dr. Sarina Tanimoto, Co-founder and CMO of ARS Pharma, the breadth of research presented solidifies the importance of neffy as a solution for managing allergy emergencies. Each presentation serves as a testament to the positive results observed in clinical settings, reaffirmed by multiple case reports highlighting diverse patient experiences.
Exploring Meeting Details
The conference showcases a variety of presentations scheduled from November 6-10, 2025, with attendees encouraged to engage at booth #400, where further information about neffy (epinephrine nasal spray) will be available.
Scheduled Presentations Overview
Key oral and poster presentations will outline various aspects of neffy, including:
- Oral Presentation:
"Real World Data on the Effectiveness of Epinephrine Nasal Spray in Clinical Practice – Update" on November 8. - Poster Presentations:
These will cover topics such as anxiety management in patients using different epinephrine delivery systems, and the assessment of dosing techniques.
About Neffy®
neffy® is designed for urgent treatment of anaphylactic reactions in both adults and pediatric patients aged four years and older. Its development reflects a crucial step in addressing the urgent need for accessible epinephrine treatments amidst rising allergy cases.
Understanding Anaphylaxis and Its Treatment
Anaphylaxis can manifest rapidly following exposure to allergens and necessitates immediate intervention with epinephrine. ARS Pharma aims to ensure that patients and their caregivers are equipped with the necessary tools to act swiftly in these critical moments. The ease of use associated with neffy is intended to alleviate some of the anxieties associated with traditional epinephrine administrations.
Frequently Asked Questions
What is Neffy®?
neffy® is an epinephrine nasal spray indicated for emergency treatment of type I allergic reactions, including anaphylaxis.
How is Neffy® different from traditional epinephrine injectors?
Neffy offers a needle-free administration method, enhancing convenience and potentially increasing compliance in emergency situations.
What data will be presented at the ACAAI meeting?
ARS Pharma will present real-world data affirming the effectiveness of neffy in treating anaphylaxis, alongside numerous case studies.
Is Neffy® suitable for all ages?
Yes, it is indicated for use in patients aged four years and older, suitable for both children and adults experiencing severe allergic reactions.
Where can I learn more about Neffy®?
For additional information, you can visit ARS Pharmaceuticals’ official website.
